FDA Converts Fabhalta Approval After Two-Year Kidney Data
The FDA first approved Fabhalta for IgAN through the accelerated approval pathway in August 2024. At that stage, the agency authorized the drug to reduce proteinuria in adults at risk of rapid disease progression.
However, the original decision relied on proteinuria as a surrogate endpoint. The data showed that Fabhalta reduced protein in the urine after nine months, but they did not yet confirm that the treatment could preserve kidney function over a longer period.
Now, the FDA has granted traditional approval for Fabhalta to slow kidney function decline. As a result, Novartis has moved beyond an approval based mainly on a predictive marker and has confirmed a direct clinical benefit for patients.
Confirmatory Trial Delivers the Evidence Needed for Full Approval
Novartis supported the conversion with final results from the placebo-controlled phase 3 APPLAUSE-IgAN trial. The study evaluated estimated glomerular filtration rate, or eGFR, over two years.
The results showed a statistically significant and clinically meaningful improvement in kidney function decline among patients who received Fabhalta. Therefore, the confirmatory study answered the central question that remained after the accelerated approval.
The earlier findings demonstrated an effect on proteinuria. In contrast, the final data showed that the treatment could slow the underlying loss of kidney function over time.
Proteinuria Opened the Door—eGFR Secured Fabhalta’s Approval
Proteinuria has become an increasingly accepted surrogate marker because it can help predict the risk of kidney failure. However, regulators still require stronger evidence when companies seek to confirm long-term clinical benefit.
In this case, the two-year eGFR results gave the FDA the evidence needed to convert the approval. Moreover, the findings connected the earlier reduction in proteinuria with a measurable effect on kidney function.
This transition highlights an important regulatory principle. Surrogate endpoints can support earlier patient access, but confirmatory trials must verify whether the expected clinical benefit actually occurs.
Accelerated Approval Comes With Growing Regulatory Pressure
The Fabhalta decision also shows that accelerated approval does not complete the regulatory process. Instead, it creates a continuing obligation for the sponsor to deliver reliable confirmatory evidence.
Companies must therefore plan endpoint selection, data governance and long-term follow-up from the beginning of development. Weak or inconclusive confirmatory data can delay traditional approval and create uncertainty around an existing indication.
Novartis Strengthens Its IgAN Lead With Fabhalta’s Full FDA Nod
The traditional approval strengthens Novartis’ growing presence in the IgAN market. Alongside Fabhalta, the company has secured accelerated approval for Vanrafia and continues to test zigakibart in a phase 3 study.
However, the wider regulatory message extends beyond one company or treatment. Pharmaceutical teams must connect early endpoint strategies with credible long-term outcomes, controlled data and clear post-approval commitments.
Zamann Pharma’s Quality Management System service helps pharmaceutical teams strengthen compliant quality processes, regulatory coordination and evidence-based decision-making across the product lifecycle. Explore the service to build a quality system that can support changing regulatory expectations and long-term compliance.
Source: Fiercepharma.Com